TRIL

NASDAQ

Trillium Therapeutics Inc.

SectorHealth CareIndustryMajor PharmaceuticalsIPOn/a

News25/Ratings5

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Price$19.30-0.61 (-3.06%)

2025-10-202026-01-23

News · 26 weeks10%

2025-10-262026-04-19

Mix090d

No activity.

Latest news

25 items

97dPR
Defiance ETFs Announces Closure of Select Funds
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq: Defiance Leveraged Long + Income PLTR ETF (NASDAQ:PLT)Defiance Leveraged Long + Income SMCI ETF (NASDAQ:SMCC)Defiance Leveraged Long + Income HOOD ETF (NASDAQ:HOOI)Defiance Leveraged Long + Income Ethereum ETF (NASDAQ:ETHI)Defiance Leveraged Long + Income AMD ETF (NASDAQ:AMDU)Defiance Leveraged Long + Income HIMS ETF (NASDAQ:HIMY)Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL)Defiance Daily Target 2X Short LLY ETF (LLYZ) The Board of Trustees of Tidal Trust II approved this action as part of Defia
205dPR
Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the first ETF designed to give investors exposure to the exclusive group of companies and crypto assets with market capitalizations above $1 trillion (the "Trillion Dollar Assets"). TRIL seeks to track the performance, before fees and expenses, of the BITA Trillion Dollar Club Index, which includes U.S. exchange-listed companies and U.S.-listed crypto ETFs tied to assets valued at $1 trillion or greater. As of September 15, 2025, the trillion-dollar club included Tesla, Alphabet,
1142dNEWS
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Conference (CCC), at the Fontainebleau Miami Beach Hotel in Florida. Together with superb keynote speakers and specialized leaders in psychedelics advisory, let’s take a glimpse at some of the leaders of well-established psychedelics companies on the speakers’ list of this exciting event. Najla Guthrie, CEO Of Wellbeing Digital Sciences And A Scientific Visionary Guthrie is CEO of one of the busiest companies among publicly-traded psychedelics firms. We’re also glad to say she’
1401dNEWS
10 Psychedelics CEOs To Pay Attention To In 2022
By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public. Businesses around the globe are researching and developing new drugs based on psychedelic properties to support a whole host of conditions. Some of the most active companies to watch boast impressive CEOs to keep an eye on in 2022. Here are a few to watch closely: Amy Emerson - MAPS Public Benefit Corporation (MAPS PBC) Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Associati
1406dPR
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini
1606dSEC
SEC Form 15-12B filed by Trillium Therapeutics Inc.
15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)
1613dSEC
SEC Form EFFECT filed by Trillium Therapeutics Inc.
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
1613dSEC
SEC Form EFFECT filed by Trillium Therapeutics Inc.
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
1616dINSIDER
SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Pucci Paolo
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Myers Scott Dunseth
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4: Harrison Rosemary returned 75 shares to the company, closing all direct ownership in the company
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Beshar Luke M
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Parsons James T.
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Kamarck Michael E.
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Looker Benjamin
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Mackey Catherine J
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Bruns Ingmar
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Petrova Penka
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Uger Robert
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Tayton-Martin Helen Katrina
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616dINSIDER
SEC Form 4 filed by Skvarka Jan
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
1616d13D/G
SEC Form SC 13D/A filed by Trillium Therapeutics Inc. (Amendment)
SC 13D/A - Trillium Therapeutics Inc. (0001616212) (Subject)
1618dSEC
SEC Form S-8 POS filed by Trillium Therapeutics Inc.
S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
1618dSEC
SEC Form POSASR filed by Trillium Therapeutics Inc.
POSASR - Trillium Therapeutics Inc. (0001616212) (Filer)